MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • MDS Virtual Congress 2020

    Home validation of a smartphone-based tapping task to assess medication responsiveness in Parkinson’s disease

    S. Broeder, R. Bussels, S. Vanden Schoor, G. Roussos, J-J. Orban deXivry, A. Nieuwboer (Leuven, Belgium)

    Objective: To validate a timed tapping task (TTT) on a smartphone to ascertain differences in OFF- and ON-phases in Parkinson’s disease (PD) in the home…
  • 2019 International Congress

    Laboratory Performance of the DopaFuse® Delivery System

    R. Draper, J. Harmon, A. Heller, B. Heller, E. Heller, C. King, T. Lau, P. Plante, J. Spiridigliozzi (Austin, TX, USA)

    Objective: SynAgile has developed the DopaFuse Delivery System to noninvasively and continuously administer levodopa/carbidopa (LD/CD) into the mouths of patients with Parkinson’s Disease (PD). The…
  • 2019 International Congress

    Preclinical Development of a Novel Carbidopa/Levodopa Precision Olfactory Delivery (POD®) Drug-Device Combination Product for the Treatment of OFF Episodes in Parkinson’s Disease

    K. Satterly, G. Davies, B. Gajera, J. Wright, H. Lin, S. Muppaneni, K. To, S. Shrewsbury, J. Hoekman (Seattle, WA, USA)

    Objective: This series of preclinical studies of novel levodopa and carbidopa/levodopa powder formulations delivered by the POD device to rats and non-human primates (NHP) guided…
  • 2019 International Congress

    Study on the effect of levodopa administration on serum zinc levels in Parkinson’s disease patients

    H. Matsuyama, K. Matsuura, H. Ishikawa, Y. Hirata, N. Kato, A. Niwa, Y. Narita, H. Tomimoto (Tsu, Japan)

    Objective: Since zinc-chelating action of levodopa has been reported in the past, we measured serum zinc level in patients with Parkinson's disease (PD) at our…
  • 2019 International Congress

    Liquid Levodopa/Carbidopa – An underutilized, cost effective treatment of advanced Parkinson’s disease in the developing world

    A. Panwar, N. Sawal (Chandigarh, India)

    Objective: Advanced Parkinson’s disease manifests with  “on-off” phenomenon, dyskinesias and increasing symptom severity . Managing it in developing countries is difficult given the low per…
  • 2019 International Congress

    Impaired fonction of mirror neurons and the role of levodopa in PD patients

    T. Danaila, P. Jaulent, C. Laurencin, J. Xie, H. Klinger, P. Krolak-Salmon, S. Thobois (Lyon, France)

    Objective: Study of the emotional mirroring and its modulation by levodopa treatment in fluctuating PD patients with no significant cognitive burden as assessed by regular…
  • 2019 International Congress

    Dopamine receptor variants alter outcomes with levodopa in early-stage Parkinson’s disease

    D. Fischer, P. Auinger, J. Goudreau, A. Cole-Strauss, K. Kieburtz, J. Elm, M. Hacker, P. Charles, J. Lipton, B. Pickut, C. Sortwell (Grand Rapids, MI, USA)

    Objective: To examine if specific single nucleotide polymorphisms (SNPs) in the genes for dopamine receptors 2 and 3 (DRD2, DRD3) correlate with worse outcomes within specific…
  • 2019 International Congress

    Impact of ND0612 on patient reported outcomes: A blinded rater study of 2 dosing regimens

    F. Stocchi, W. Poewe, S. Oren, R. Case, K. Kieburtz, C. Olanow (Rome, Italy)

    Objective: Primary analyses of this Phase 2 study have demonstrated significant efficacy of ND0612 in reducing OFF time and improving motor status. This secondary analysis…
  • 2019 International Congress

    Trends in first line therapy for PD in Wales: A 16 year observational study

    K. Orayj, A. Lacey, A. Akbari, O. Pickrell, E. Lane (Cardiff, United Kingdom)

    Objective: To examine the changes in first line therapy of newly diagnosed Parkinson’s patients between 2000 and 2016 in Wales. Background: There have been several…
  • 2019 International Congress

    Pharmacokinetics of ABBV-951 Following 24-Hour Continuous Subcutaneous Infusion to Arm, Abdomen and Thigh

    M. Rosebraugh, P. Kym, W. Liu, M. Facheris, J. Benesh (North Chicago, IL, USA)

    Objective: Characterize levodopa pharmacokinetics (PK) and safety/tolerability of ABBV-951 in healthy volunteers at 3 different subcutaneous (SC) infusion sites: Arm, Abdomen and Thigh Background: As…
  • « Previous Page
  • 1
  • …
  • 31
  • 32
  • 33
  • 34
  • 35
  • …
  • 62
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley